Logotipo del repositorio
 

Clinical experience with the use of Neoadjuvant hormone therapy for Breast Cancer in a Latin American cancer center

Vista sencilla de ítem
dc.contributor.authorDíaz, Sandra
dc.contributor.authorSerrano, Wilmar
dc.contributor.authorSánchez, Ricardo
dc.contributor.authorOrozco, Martha Cecilia
dc.contributor.authorMendoza, Sara
dc.contributor.authorNuñez-Lemus, Marcela
dc.contributor.authorGarcía, Mauricio
dc.contributor.authorLehmann, Carlos
dc.contributor.authorAngel, Javier
dc.contributor.authorDuarte, Carlos
dc.contributor.authorGuzman, Luis
dc.contributor.authorCervera, Sergio
dc.contributor.authorOsorio, Ana María
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Cirugía y Especialidades. Grupo de Investigación de Cirugía y Especialidadesspa
dc.date.accessioned2021-05-31T14:21:22Z
dc.date.available2021-05-31T14:21:22Z
dc.date.created2020-05-25
dc.description.abstractenglishIntroduction: The most frequent subtype of breast cancer is the luminal one, in 70 to 80% of cases; the poor response to neoadjuvant hemotherapy of these tumors positions neoadjuvant hormone therapy as atreatment option. Materials and Methods: An observational, descriptive, historical cohort study was conducted in patients with hormone receptor (HR positive and HER2-positive breast cancer, managed with neoadjuvant hormonetherapy in the INC (National Cancer Institute, for its initials in spanish), with the aim of evaluating theirclinical and pathological response. Results: 57 patients were managed with neoadjuvant hormone therapy. Most stage IIA patients (40.3%, n = 23). 86% (n = 49) had luminal A tumors. Letrozole was the most widely used drug, in 78.9% (n = 45). The overall response rate (ORR) was reached in 94.6% (n = 53); and 10.7% of the patients (n = 6) achieved complete clinical response (cCR). Complete pathological response (pCR) was achieved only in one patient. Conservative surgery was possible in 56.9% (n = 29) of the patients. There was no difference between the type of aromatase inhibitor (AI) and the duration of neoadjuvant hormonal treatment with the clinical response. With a median follow-up of 3 years (0.6 and 6 years), no disease progression was reported in any of the patients in the study. Conclusion: The results of this study support the neoadjuvant hormone therapy recommendations for postmenopausal patients older than 65 years with luminal breast cancer, with well or moderately differentiated tumors, strongly HR positive and low Ki 67.spa
dc.description.indexingRevista Internacional - No indexadaspa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.identifierhttps://www.sciencerepository.org/clinical-experience-with-the-use-of-neoadjuvant-hormone-therapy-for_JSO-2020-3-108spa
dc.identifier.doihttp://dx.doi.org/10.31487/j.JSO.2020.03.08spa
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.issn2674-3000spa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.identifier.urihttp://hdl.handle.net/10554/53910
dc.language.isoengspa
dc.relation.citationendpage6spa
dc.relation.citationissue3spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume3spa
dc.relation.ispartofjournalJournal of Surgical Oncologyspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenceAtribución-NoComercial 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.keywordBreast neoplasmsspa
dc.subject.keywordAromatase inhibitorsspa
dc.subject.keywordTamoxifenspa
dc.subject.keywordEstrogen receptorsspa
dc.subject.keywordSegmental mastectomyspa
dc.titleClinical experience with the use of Neoadjuvant hormone therapy for Breast Cancer in a Latin American cancer centerspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.localArtículo de revistaspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
clinical-experience-with-the-use-of-neoadjuvant-hormone-therapy-for_JSO-2020-3-108.pdf
Tamaño:
322.46 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.54 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos